跳至主要内容
临床试验/CTRI/2018/11/016306
CTRI/2018/11/016306Other未知

Multicenter, Observational Registry to Study the Safety and Efficacy of Biosimilar Trastuzumab Intravenous Infusion in Patients with Early Breast Cancer

Biocon Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
Other

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patient aged ââ?°Â¥ 18 years
  • Patients who are willing to provide written and signed informed consent for collecting health data into the registry
  • Patients with EBC who are eligible to receive treatment with Trastuzumab as per the approved prescribing information and clinical judgment of the treating oncologist

排除标准

  • 1.Have a history of hypersensitivity to Trastuzumab or other components of the product
  • 2.Patient with any contraindication as mentioned in approved prescribing information of Trastuzumab biosimilar
  • 3.Any other reason (concurrent disease or condition) in the opinion of the oncologist that would make the patient unsuitable for participation in the registry

研究者

相似试验

Observational non-interventional registry study of... | 临床试验